Free Trial Information
BioCentury | May 30, 2011
Finance

Europe's Iceberg 2011: Unlocking hidden value

...NYSE:ACL) $589 (A) 2011 Eurand N.V. Axcan Pharma Inc. (now Aptalis Pharma Inc.) $583 2006 NeuTec Pharma plc...
Read More
BioCentury | Sep 1, 2008
Clinical News

Aurograb: Phase II data

...the data. Novartis acquired rights to the compound as part of its 2006 acquisition of NeuTec Pharma plc...
Read More
BioCentury | Aug 29, 2008
Top Story

Novartis dropping Aurograb

...recombinant antibody against ATP binding cassette (ABC) transporter as part of its 2006 acquisition of NeuTec...
Read More
BioCentury | Dec 24, 2007
Strategy

Novartis' antibody deals

...site, as well as an option to optimization technology for non-therapeutic antibodies 2006 NeuTec Acquired NeuTec...
Read More
BioCentury | Dec 24, 2007
Strategy

Antibodies: Back to the future

...a dozen deals in the antibody/protein space, including the £305 million ($627 million) acquisition of NeuTec Pharma plc...
Read More
BioCentury | Dec 11, 2006
Finance

Top U.K. financings

...Placing and open £27.1 ($48.3) Innovata (formerly ML Labs) 7/12/05 Placing and open £26.1 ($45.4) NeuTec...
Read More
BioCentury | Nov 20, 2006
Clinical News

Mycograb regulatory update

...information to CHMP in support of Mycograb's approval. NVS acquired Mycograb through its acquisition of NeuTec Pharma plc...
Read More
BioCentury | Jul 3, 2006
Finance

3rd Quarter Stock Preview: Wanted: Inflows

...LSE:AZN; AZN, London, U.K.) for $1 billion and $210 million in cash, respectively. More recently, NeuTec Pharma plc...
Read More
BioCentury | Jun 19, 2006
Clinical News

Aurograb: Completed Phase III enrollment

...patients in a double-blind, placebo-controlled, European Phase III trial to treat methicillin-resistant S. aureus (MRSA). NeuTec Pharma plc...
Read More
BioCentury | Jun 16, 2006
Clinical News

NeuTec enrolls Aurograb Phase III

NeuTec (LSE:NTP) completed enrollment of 161 patients in a double-blind, placebo-controlled European Phase III trial of Aurograb plus vancomycin to treat methicillin-resistant S. aureus (MRSA) infection. The primary endpoint is a combination of culture clearance...
Read More
Items per page:
1 - 10 of 48
BioCentury | May 30, 2011
Finance

Europe's Iceberg 2011: Unlocking hidden value

...NYSE:ACL) $589 (A) 2011 Eurand N.V. Axcan Pharma Inc. (now Aptalis Pharma Inc.) $583 2006 NeuTec Pharma plc...
Read More
BioCentury | Sep 1, 2008
Clinical News

Aurograb: Phase II data

...the data. Novartis acquired rights to the compound as part of its 2006 acquisition of NeuTec Pharma plc...
Read More
BioCentury | Aug 29, 2008
Top Story

Novartis dropping Aurograb

...recombinant antibody against ATP binding cassette (ABC) transporter as part of its 2006 acquisition of NeuTec...
Read More
BioCentury | Dec 24, 2007
Strategy

Novartis' antibody deals

...site, as well as an option to optimization technology for non-therapeutic antibodies 2006 NeuTec Acquired NeuTec...
Read More
BioCentury | Dec 24, 2007
Strategy

Antibodies: Back to the future

...a dozen deals in the antibody/protein space, including the £305 million ($627 million) acquisition of NeuTec Pharma plc...
Read More
BioCentury | Dec 11, 2006
Finance

Top U.K. financings

...Placing and open £27.1 ($48.3) Innovata (formerly ML Labs) 7/12/05 Placing and open £26.1 ($45.4) NeuTec...
Read More
BioCentury | Nov 20, 2006
Clinical News

Mycograb regulatory update

...information to CHMP in support of Mycograb's approval. NVS acquired Mycograb through its acquisition of NeuTec Pharma plc...
Read More
BioCentury | Jul 3, 2006
Finance

3rd Quarter Stock Preview: Wanted: Inflows

...LSE:AZN; AZN, London, U.K.) for $1 billion and $210 million in cash, respectively. More recently, NeuTec Pharma plc...
Read More
BioCentury | Jun 19, 2006
Clinical News

Aurograb: Completed Phase III enrollment

...patients in a double-blind, placebo-controlled, European Phase III trial to treat methicillin-resistant S. aureus (MRSA). NeuTec Pharma plc...
Read More
BioCentury | Jun 16, 2006
Clinical News

NeuTec enrolls Aurograb Phase III

NeuTec (LSE:NTP) completed enrollment of 161 patients in a double-blind, placebo-controlled European Phase III trial of Aurograb plus vancomycin to treat methicillin-resistant S. aureus (MRSA) infection. The primary endpoint is a combination of culture clearance...
Read More
Items per page:
1 - 10 of 48